Aller au contenu principal
Brukinsa (Zanubrutinib) 80 mg – Targeted Therapy for Blood Cancers  Brukinsa (Zanubrutinib) - Macrocare Health Blog

Brukinsa (Zanubrutinib) 80 mg – Targeted Therapy for Blood Cancers Brukinsa (Zanubrutinib)

Brukinsa (Zanubrutinib) is a targeted therapy used to treat certain blood cancers and lymphomas. It works by blocking specific pathways that help cancer cells grow and survive.

 

What is Brukinsa (Zanubrutinib)?

Brukinsa belongs to a class of medications known as Bruton's Tyrosine Kinase (BTK) Inhibitors.

BTK plays an important role in the growth and survival of certain cancerous lymphocytes. Brukinsa works by:

  • Blocking cancer cell growth signals
  • Reducing abnormal cell proliferation
  • Helping improve disease control

In simple terms:
It targets a key pathway that certain blood cancers depend on for growth.

 

Indications

Brukinsa (Zanubrutinib) is used in:

  • Certain types of lymphomas
  • Chronic Lymphocytic Leukemia (CLL) in selected cases
  • Other blood cancers according to treatment protocols

 

Dosage and Administration

  • Standard dose: 80 mg according to the treatment protocol
  • Taken orally
  • Once or twice daily depending on the treatment plan
  • Should be taken exactly as prescribed by the physician

 

Common Side Effects

May include:

  • Low blood cell counts
  • Fatigue
  • Mild bruising or bleeding
  • Diarrhea
  • Mild infections
  • Muscle or joint pain

Regular medical monitoring is important during treatment.

 

Monitoring During Treatment

Patients on Brukinsa (Zanubrutinib) require:

  • Regular complete blood count (CBC) monitoring
  • Monitoring for signs of infection or bleeding
  • Assessment of treatment response
  • Evaluation of overall health status

 

Availability & How to Access Treatment

Brukinsa (Zanubrutinib) is available through Macrocare’s approved partners.

You can now request and access the medication easily through us.

WhatsApp contact for medication requests:
Click here

 

Brukinsa (Zanubrutinib) Brukinsa (Zanubrutinib) 80 mg is a targeted therapy for blood cancers and lymphomas that works by blocking cancer cell growth signals and helping improve disease control.

 

Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.

 

Autres articles

Saisir le numéro de mobile

Veuillez indiquer votre numéro de téléphone afin que nous puissions vous contacter pour en savoir plus sur votre problème de santé.

Confidentialité protégée : vos informations médicales et personnelles restent entièrement confidentielles et sécurisées grâce à une protection conforme aux normes du secteur.

CONTACTEZ-NOUS

Contactez-nous

Veuillez indiquer votre numéro de téléphone afin que nous puissions vous contacter pour en savoir plus sur votre problème de santé.

Ligne directe

+20 106 604 2282

Appeler

Adresse e-mail

[email protected]

Écrire